Status:
COMPLETED
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Telik
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung canc...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Histologically confirmed non-small cell lung cancer (NSCLC)
- Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and radiation)
- Measurable disease by RECIST
- ECOG status of 0-1
- Adequate liver and renal function
- Adequate bone marrow reserves
Exclusion
- Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC
- Up to one prior adjuvant or neoadjuvant chemotherapy is allowed
- History of bone marrow transplantation or stem cell support
- Pregnant or lactating women
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00088556
Start Date
August 1 2004
End Date
May 1 2009
Last Update
May 31 2012
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Bay Area Cancer Research Group
Concord, California, United States, 94520
2
East Bay Medical Oncology/Hematology Associates
Concord, California, United States, 94520
3
Southwest Cancer Care
Escondido, California, United States, 92025
4
Kaiser Permanente Medical Center
Hayward, California, United States, 94545